Literature DB >> 21593346

Fluorescence in situ hybridisation analysis of formalin-fixed paraffin-embedded tissue sections in the diagnostic work-up of non-Burkitt high grade B-cell non-Hodgkin's lymphoma: a single centre's experience.

Nicola J Foot1, Robert G Dunn, Helen Geoghegan, Bridget S Wilkins, Michael J Neat.   

Abstract

AIMS: In recent years the genetic aberrations associated with diffuse large B-cell lymphoma and the new subtype described in the 2008 revision of the WHO classification, 'B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma' have been increasingly well defined. Recurrent genetic abnormalities include rearrangements involving MYC (8q24), BCL2 (18q21) and BCL6 (3q27); as the prognostic and therapeutic implications associated with these abnormalities are clarified their accurate identification at diagnosis is becoming increasingly critical. We describe our experience of using a panel of fluorescence in situ hybridisation (FISH) probes on formalin-fixed paraffin-embedded tissue sections in the diagnostic work-up of 162 patients with non-Burkitt high grade B-cell non-Hodgkin's lymphomas (HG-BNHL).
METHODS: BCL6, IGH-BCL2 and MYC status were determined prospectively in sequential patients presenting with HG-BNHL, with respect to the presence of rearrangements and copy number changes. Small numbers of samples were analysed retrospectively or were studied at relapse in previously untested patients.
RESULTS: FISH analysis was successful in 160/162 (99%) cases, with abnormalities detected in 118/160 (74%).
CONCLUSIONS: FISH analysis of formalin-fixed paraffin-embedded tissue sections is a highly reproducible technique with an excellent success rate for the detection of genetic abnormalities which will play an increasingly important role in improving risk stratification of patients with HG-BNHL.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21593346     DOI: 10.1136/jclinpath-2011-200015

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  13 in total

Review 1.  Biology of double-hit B-cell lymphomas.

Authors:  R Coleman Lindsley; Ann S LaCasce
Journal:  Curr Opin Hematol       Date:  2012-07       Impact factor: 3.284

2.  Burkitt leukaemia/lymphoma: R-CODOX-M/R-IVAC remains gold standard treatment in BL.

Authors:  L Smyth; P V Browne; E Conneally; C Flynn; P Hayden; M Jeffers; D O'Brien; F Quinn; J Kelly; M Perera; G M Crotty; M Leahy; B Hennessy; F Jackson; M Ryan; E Vandenberghe
Journal:  Ir J Med Sci       Date:  2015-04-07       Impact factor: 1.568

3.  Clinical and pathological aspects of human immunodeficiency virus-associated plasmablastic lymphoma: analysis of 24 cases.

Authors:  Yusuke Koizumi; Tomoko Uehira; Yasunori Ota; Yoshihiko Ogawa; Keishiro Yajima; Junko Tanuma; Mihoko Yotsumoto; Shotaro Hagiwara; Satoshi Ikegaya; Dai Watanabe; Hitoshi Minamiguchi; Keiko Hodohara; Kenta Murotani; Hiroshige Mikamo; Hideho Wada; Atsushi Ajisawa; Takuma Shirasaka; Hirokazu Nagai; Yoshinori Kodama; Tsunekazu Hishima; Makoto Mochizuki; Harutaka Katano; Seiji Okada
Journal:  Int J Hematol       Date:  2016-09-07       Impact factor: 2.490

4.  The t(14;18)(q32;q21) with extra MYC signal - is it a gray zone lymphoma?

Authors:  Qin A Chang; Abdulraheem Qasem; Sheshadri Madhusudhana; Alexey Glazyrin
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

5.  Diagnosis and subtyping of de novo and relapsed mediastinal lymphomas by endobronchial ultrasound needle aspiration.

Authors:  Mufaddal T Moonim; Ronan Breen; Paul A Fields; George Santis
Journal:  Am J Respir Crit Care Med       Date:  2013-11-15       Impact factor: 21.405

6.  MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.

Authors:  Alexandra Valera; Armando López-Guillermo; Teresa Cardesa-Salzmann; Fina Climent; Eva González-Barca; Santiago Mercadal; Iñigo Espinosa; Silvana Novelli; Javier Briones; José L Mate; Olga Salamero; Juan M Sancho; Leonor Arenillas; Sergi Serrano; Nadina Erill; Daniel Martínez; Paola Castillo; Jordina Rovira; Antonio Martínez; Elias Campo; Luis Colomo
Journal:  Haematologica       Date:  2013-05-28       Impact factor: 9.941

Review 7.  The impact of MYC rearrangements and "double hit" abnormalities in diffuse large B-cell lymphoma.

Authors:  Pei Lin; L Jeffrey Medeiros
Journal:  Curr Hematol Malig Rep       Date:  2013-09       Impact factor: 3.952

8.  Classification of AIDS-related lymphoma cases between 1987 and 2012 in Japan based on the WHO classification of lymphomas, fourth edition.

Authors:  Yasunori Ota; Tsunekazu Hishima; Makoto Mochizuki; Yoshinori Kodama; Suzuko Moritani; Naoki Oyaizu; Sohtaro Mine; Atsushi Ajisawa; Junko Tanuma; Tomoko Uehira; Shotaro Hagiwara; Keishiro Yajima; Yusuke Koizumi; Takuma Shirasaka; Yuki Kojima; Hirokazu Nagai; Yoshiyuki Yokomaku; Yumiko Shiozawa; Tomohiko Koibuchi; Aikichi Iwamoto; Shinichi Oka; Hideki Hasegawa; Seiji Okada; Harutaka Katano
Journal:  Cancer Med       Date:  2014-01-10       Impact factor: 4.452

9.  IGH amplification in patients with B cell lymphoma unclassifiable, with features intermediate between diffuse large B cell lymphoma and Burkitt's lymphoma.

Authors:  Michael Bellone; Ann-Leslie Zaslav; Tahmeena Ahmed; Htien L Lee; Yupo Ma; Youjun Hu
Journal:  Biomark Res       Date:  2014-05-09

10.  The prognosis of MYC translocation positive diffuse large B-cell lymphoma depends on the second hit.

Authors:  Alexandra Clipson; Sharon Barrans; Naiyan Zeng; Simon Crouch; Nicholas F Grigoropoulos; Hongxiang Liu; Sylvia Kocialkowski; Ming Wang; Yuanxue Huang; Lisa Worrillow; John Goodlad; Jenny Buxton; Michael Neat; Paul Fields; Bridget Wilkins; John W Grant; Penny Wright; Hesham Ei-Daly; George A Follows; Eve Roman; A James Watkins; Peter W M Johnson; Andrew Jack; Ming-Qing Du
Journal:  J Pathol Clin Res       Date:  2015-03-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.